Floatz logo

Elbasvir

Fibrosis, Liver

Institute Of Cardiology & Internal Diseases, KazakhstanSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

27 Active assets in the Fibrosis, Liver cohort.

Asset / SponsorPhaseRating
Entecavir
Tanta University
Phase 4BB
Peg-Intron
Beth Israel Deaconess Medical Center
Phase 4BB
COLCHICINUM
Zagazig University
Phase 4BB
Peg-Ifn
Beijing Friendship Hospital
Phase 4BB
Hydronidone
Beijing Continent Pharmaceutical Co, Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

Elbasvir is also rated in:

hepatitis C virus infectionDormant
BBB
Indicative ·
75 / 100
View asset →
chronic hepatitis C virus infectionDormant
BBB
Indicative ·
72 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →